Press release, 1 November 2023 at 10:45 a.m. (EET) 

A research study abstract submitted by experts from Nightingale Health has won the American Heart Association's Paul Dudley White International Scholar Award. The award is given to the highest ranked research study abstract submitted from each country to the American Heart Association's Scientific Sessions 2023. The award is named after Dr. Paul Dudley White, who was a founder of the American Heart Association and an early leader in preventative cardiology. 

The study "Metabolomic Biomarker Profiling Improves Cardiovascular Risk Assessment for Patients on Statins: Evidence From 35,000 Individuals from the United Kingdom" found that Nightingale Health's proprietary blood test enhanced the accuracy of cardiovascular risk prediction beyond established risk factors for people who are taking cholesterol-lowering medication (statins). This finding has potential for improving heart disease risk assessment in the substantial population already on statins, guiding doctors to allocate additional therapies to the ones who can benefit from them the most. 

"We are delighted for this recognition that our abstract has received. The award recognizes the predictive and preventative power of Nightingale Health's blood analysis results. The findings, along with numerous others from scientists worldwide using Nightingale Health's biomarker data, are paving the way for the transition of preventative health tools from research to clinical use, as already demonstrated in Finland, where Nightingale Health's blood test is being rolled out in nationally significant scale in occupational healthcare," said Peter Würtz, Co-founder and Scientific Director of Nightingale Health, who was also one of the authors of the abstract.  

Peter Würtz and co-authors will be acknowledged during the American Heart Association's Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania, USA, from November 11 to 13, 2023. During the event, Peter Würtz will also be presenting the findings from the award-winning abstract. 

Nightingale Health's scientific experts will also be attending the world's largest human genetics and genomics meeting and exposition, the American Society of Human Genetics' Annual Meeting (ASHG), in Washington, DC from November 1 to 5, 2023. The company's Chief Scientific Officer, Jeffrey Barrett, and Senior Data Scientist, Sini Kerminen, will be giving presentations on the latest scientific breakthroughs made with Nightingale Health's analysis results at the event. 

More about Nightingale Health's participation at American Heart Association Scientific Sessions 2023 (AHA) 

https://research.nightingalehealth.com/meet-us-at-aha-2023

https://professional.heart.org/en/meetings/scientific-sessions

More about Nightingale Health's participation at American Society of Human Genetics Annual Meeting (ASHG) 

https://research.nightingalehealth.com/meet-us-at-ashg-2023

https://ashg.org/meetings/2023meeting

For further information, please contact: 

Teemu Suna, CEO 
ir@nightingalehealth.com

About Nightingale Health 

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it's also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years. 

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 530 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com